GlassScriptPhysician profile
Whitney A Pitman
NPI 1497095970
$1,846.98
in general payments reported to CMS, 2019-2025
19 companies · $36.18 in 2025
The $36.18 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,226 · 2022: $221 · 2023: $348 · 2024: $16.11 · 2025: $36.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $681.41 | 2021-2023 | |
| Amgen INC. | $513.73 | 2021-2023 | Lumakras, Xgeva, Nplate |
| Stemline Therapeutics INC. | $99.34 | 2023 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $87.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.53 | 2021-2023 | Keytruda, Lynparza |
| Incyte Corporation | $50.20 | 2021-2023 | Jakafi |
| Lilly USA, LLC | $49.68 | 2021 | |
| Puma Biotechnology, INC. | $47.99 | 2021 | |
| Foundation Medicine, INC. | $47.24 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.88 | 2021 | |
| Emd Serono, INC. | $21.84 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $20.68 | 2025 | |
| Daiichi Sankyo INC. | $19.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.64 | 2022 | |
| Genzyme Corporation | $17.86 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $16.11 | 2024 | Restrata Wound Matrix |
| Reprise Biomedical, INC. | $15.50 | 2025 | Miro 3d |
| Urgo Medical North America, LLC | $14.90 | 2023 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Rigel Pharmaceuticals, INC. | $14.24 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Pitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.